Bank of Montreal’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-215,041
| Closed | -$8.65M | – | 3842 |
|
|
2026
Q1 | $8.65M | Buy |
215,041
+38,470
| +22% | +$829K | ﹤0.01% | 1135 |
|
|
2025
Q4 | $4.44M | Buy |
176,571
+16,265
| +10% | +$382K | ﹤0.01% | 1371 |
|
|
2025
Q3 | $3.63M | Buy |
160,306
+693
| +0.4% | +$16.2K | ﹤0.01% | 1436 |
|
|
2025
Q2 | $2.76M | Buy |
159,613
+1,040
| +0.7% | +$19.3K | ﹤0.01% | 1469 |
|
|
2025
Q1 | $3.47M | Buy |
158,573
+77,582
| +96% | +$2.14M | ﹤0.01% | 1311 |
|
|
2024
Q4 | $2.58M | Buy |
80,991
+41,635
| +106% | +$1.25M | ﹤0.01% | 1456 |
|
|
2024
Q3 | $1.16M | Sell |
39,356
-92,962
| -70% | -$3.44M | ﹤0.01% | 1957 |
|
|
2024
Q2 | $5.36M | Sell |
132,318
-619
| -0.5% | -$28K | ﹤0.01% | 1238 |
|
|
2024
Q1 | $7.83M | Sell |
132,937
-336,947
| -72% | -$21.5M | ﹤0.01% | 1060 |
|
|
2023
Q4 | $29.6M | Buy |
469,884
+37,911
| +9% | +$1.92M | 0.01% | 646 |
|
|
2023
Q3 | $19.3M | Buy |
431,973
+354,047
| +454% | +$15.6M | 0.01% | 726 |
|
|
2023
Q2 | $7.11M | Sell |
77,926
-128,622
| -62% | -$11.1M | ﹤0.01% | 1171 |
|
|
2023
Q1 | $13.9M | Buy |
206,548
+105,617
| +105% | +$6.09M | 0.01% | 800 |
|
|
2022
Q4 | $5.22M | Sell |
100,931
-28,408
| -22% | -$1.51M | ﹤0.01% | 1268 |
|
|
2022
Q3 | $8.92K | Sell |
129,339
-38,786
| -23% | -$2.3M | ﹤0.01% | 1045 |
|
|
2022
Q2 | $7.81K | Buy |
168,125
+18
| +0% | +$821 | ﹤0.01% | 1176 |
|
|
2022
Q1 | $8.32M | Sell |
168,107
-11,574
| -6% | -$511K | ﹤0.01% | 1233 |
|
|
2021
Q4 | $8.77M | Sell |
179,681
-73,847
| -29% | -$2.91M | ﹤0.01% | 1007 |
|
|
2021
Q3 | $8.61M | Sell |
253,528
-965
| -0.4% | -$54.2K | ﹤0.01% | 1378 |
|
|
2021
Q2 | $16.3M | Buy |
254,493
+64,348
| +34% | +$3.32M | 0.01% | 1014 |
|
|
2021
Q1 | $7.9M | Buy |
190,145
+30,806
| +19% | +$1.46M | 0.01% | 1134 |
|
|
2020
Q4 | $8.97M | Sell |
159,339
-183,981
| -54% | -$7.78M | 0.01% | 1074 |
|
|
2020
Q3 | $11.2M | Buy |
343,320
+8,490
| +3% | +$254K | 0.01% | 811 |
|
|
2020
Q2 | $10.6M | Buy |
334,830
+267,330
| +396% | +$8.59M | 0.01% | 810 |
|
|
2020
Q1 | $1.76M | Sell |
67,500
-62,768
| -48% | -$2.23M | ﹤0.01% | 1480 |
|
|
2019
Q4 | $3.99M | Buy |
130,268
+126,028
| +2,972% | +$3.49M | ﹤0.01% | 1484 |
|
|
2019
Q3 | $102K | Buy |
4,240
+192
| +5% | +$5.28K | ﹤0.01% | 3280 |
|
|
2019
Q2 | $103K | Buy |
+4,048
| New | +$82.4K | ﹤0.01% | 3317 |
|
|
2019
Q1 | – | Sell |
-508
| Closed | -$7K | – | 4297 |
|
|
2018
Q4 | $7K | Buy |
508
+259
| +104% | +$3.97K | ﹤0.01% | 3972 |
|
|
2018
Q3 | $4K | Sell |
249
-7
| -3% | -$129 | ﹤0.01% | 4149 |
|
|
2018
Q2 | $6K | Buy |
+256
| New | +$5.88K | ﹤0.01% | 4072 |
|
Other funds holding APLS
Bank of Montreal's APLS Position: Q2 2026 in Review
Bank of Montreal sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 215,041 shares — an estimated $8.65M sold.
Bank of Montreal first reported a position in APLS in Q2 2018 and held it in 31 quarters. The position peaked at $29.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Bank of Montreal reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of Montreal sold 215,041 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.65M.
- Bank of Montreal first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 31 quarters.
- Bank of Montreal's Apellis Pharmaceuticals position peaked at $29.6M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.